Rational peptide-based tumour vaccine development and T cell monitoring

Seminars in Cancer Biology

Volumn 13, Issue 6, 2003, Pages 423-429

  Scheibenbogen, Carmen ^a   Letsch, Anne ^a   Schmittel, Alexander ^a   Asemissen, Anne Marie ^a   Thiel, Eckhard ^a   Keilholz, Ulrich ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

ELISPOT assay; Peptide; Tetramer; Tumour; Vaccination

Indexed keywords

TUMOR VACCINE;

ANTIGEN SPECIFICITY; ARTICLE; CLINICAL TRIAL; HUMAN; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; TUMOR REGRESSION; VACCINATION;

EID: 0742287070     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.09.006     Document Type: Article

References (46)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B.et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Renkvist N., Castelli C., Robbins P.F., Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:2001;3-15.
3. Suni M.A., Picker L.J., Maino V.C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J. Immunol. Methods. 212:1998;89-98.
4. Scheibenbogen C., Lee K.H., Mayer S., Stefanovic S., Moebius U., Herr W.et al. A sensitive ELISPOT assay for detection of CD8+ lymphocytes specific for HLA class I-peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:1997;221-226.
5. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I.et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
6. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H.et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:1999;219-230.
7. Jaeger E., Ringhoffer M., Dienes H.P., Arand M., Karbach J., Jaeger D.et al. GM-CSF enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67:1996;54-62.
8. Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P.et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:1996;37-44.
9. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L.et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.
10. Lewis J., Janetzki S., Schaed S., Panageas C., Wang S., Williams L.et al. Evaluation of CD8+ T cell frequencies by the ELISPOT assay in healthy individuals and patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer. 87:2000;391-398.
11. Scheibenbogen C., Schmittel A., Keilholz U., Allgäuer T., Hofmann U., Max R.et al. Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma. J. Immunother. 23:2000;275-281.
12. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M.et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? Review. J. Natl. Cancer Inst. 9411:2002;805-818.
13. Machiels J.P., van Baren N., Marchand M. Peptide-based cancer vaccines. Review. Semin. Oncol. 29:2002;494-502.
14. Gjertsen M.K., Buanes T., Rosseland A.R., Bakka A., Gladhaug I., Soreide O., Eriksen J.A., Moller M., Baksaas I., Lothe R.A., Saeterdal I., Gaudernack G. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer. 92:2001;441-450.
15. Knutson K.L., Schiffman S., Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107:2001;477-484.
16. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A.et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6:2000;3406-3416.
17. Jager E., Gnjatic S., Nagata Y., Stockert E., Jager D., Karbach J.et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. U.S.A. 97:2000;12198-12203.
18. Molldrem JJ, Kant S, Lu S, Rios R, Streicher H, Wang C, et al. Peptide vaccination with PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia. In: Proceeding of the American Society of Hematology, 6-10 December 2002. Abstract in Blood 100, p. 6a.
19. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A.et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20:2002;2624-2632.
20. Weber J., Sondak V.K., Scotland R., Phillip R., Wang F., Rubio V.et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer. 97:2003;186-200.
21. Khong H.T., Rosenberg S.A. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J. Immunol. 168:2002;951-956.
22. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A.et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8809-8814.
23. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A.et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:2001;6451-6458.
24. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R.et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20:2002;4169-4180.
25. Scheibenbogen C., Nagorsen D., Seliger B., Schmittel A., Bauer S., Max N.et al. Long-term freedom from recurrence in two high-risk melanoma patients following adjuvant vaccination with tyrosinase peptides. Int. J. Cancer. 99:2002;403-408.
26. Coulie P.G., Karanikas V., Colau D., Lurquin C., Landry C., Marchand M. et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10290-10295.
27. Butterfield L.H., Ribas A., Dissette V.B., Amarnani S.N., Vu H.T., Oseguera D.et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9:2003;998-1008.
28. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., Celis E. A phase I trial of an HLA-A1-restricted MAGE-3 epitope peptide with IFA in patients with resected high-risk melanoma. J. Immunother. 5:1999;431-440.
29. Wang F., Bade E., Kuniyoshi C., Spears L., Jeffrey G., Marty V.et al. Phase I trial of a MART-1 peptide vaccine with Incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5:1999;2756-2765.
30. *A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. 8:2002;967-972.
31. Scheibenbogen C., Schadendorf D., Bechrakis N., Nagorsen D., Hofmann U., Servetopoulou F.et al. Effects of GM-CSF and foreign helper protein as immunological adjuvants on the T cell response to vaccination with tyrosinase peptides. Int. J. Cancer. 104:2003;188-194.
32. Slingluff C., Yamshchikov G.V., Neese P., Galavotti H., Eastham S., Engelhard V. Phase I trial of a melanoma vaccine with gp100 280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome. Clin. Cancer Res. 7:2001;3012-3024.
33. Lee P., Wang F., Kuniyoshi J., Rubio V., Stuges T., Groshen S. Effects of IL-12 on the immune response to a multipeptide vaccine for resected melanoma. J. Clin. Oncol. 19:2001;3836-3847.
34. Smith J.W. 2nd, Walker E.B., Fox B.A., Haley D., Wisner K.P., Doran T.et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol. 21:2003;1562-1573.
35. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L.et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163:1999;1690-1695.
36. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P.et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:2000;1499-1512.
37. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwarzentruber D.et al. Cancer regression and autoimmunity induced by CTLA-4 blockade in patients with metastatic melanoma. PNAS. 100:2003;8372-8377.
38. Scheibenbogen C., Romero P., Rivoltini L., Herr W., Schmittel A., Cerrotini J.C.et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium release assay: a four-centre comparative study. J. Immunol. Methods. 244:2000;81-89.
39. Keilholz U., Weber J., Finke J.H., Gabrilovich D.I., Kast W.M., Disis M.L.et al. Immunologic Monitoring of Cancer Vaccine Therapy: results of a Workshop Sponsored by the Society for Biological Therapy. J. Immunother. 25:2002;97-138.
40. Letsch A, Scheibenbogen C. Quantification and characterization of antigen-specific T lymphocytes by ELISPOT assay and intracellular staining. Methods 2003 Oct;31(2):143-9.
41. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:1999;708-712.
42. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M., Papagno L.et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:2002;379-385.
43. Monsurro V., Nagorsen D., Wang E., Provenzano M., Dudley M.E., Rosenberg S.A.et al. Functional heterogeneity of vaccine-induced CD8(+) T cells. J. Immunol. 168:2002;5933-5942.
44. Speiser D.E., Lienard D., Pittet M.J., Batard P., Rimoldi D., Guillaume P.et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur. J. Immunol. 32:2002;731-741.
45. + memory T cells. Cancer Res 2003 Sept 1;63(17):5582-6.
46. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blan IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia, in press.